NCT06125080 (UTILIZABLE) is a Phase 2 clinical trial of Utidelone in TNBC - Triple-Negative Breast Cancer, sponsored by Huihua Xiong.

Who is sponsoring NCT06125080?

NCT06125080 is sponsored by Huihua Xiong.

What drugs are being tested in NCT06125080?

Interventions in NCT06125080: Utidelone, Tirelizumab, Bevacizumab.

What condition does NCT06125080 study?

NCT06125080 studies TNBC - Triple-Negative Breast Cancer.

Is NCT06125080 still recruiting?

NCT06125080 is currently recruiting now. Last updated 9 November 2023.

Last reviewed 2023-11-09 · How we verify

NCT06125080: UTILIZABLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study

Recruiting now Phase 2 Last updated 9 November 2023

What this trial tests

Phase 2 trial testing Utidelone in TNBC - Triple-Negative Breast Cancer in 78 participants. Currently enrolling.

Timeline

30 October 2023

Primary endpoint
30 October 2025

30 October 2026

Quick facts

Lead sponsor	Huihua Xiong
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	78
Start date	30 October 2023
Primary completion	30 October 2025
Estimated completion	30 October 2026
Sites	1 location across China

Drugs / interventions tested

Utidelone — full drug profile →
Tirelizumab — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

TNBC - Triple-Negative Breast Cancer — all drugs for TNBC - Triple-Negative Breast Cancer →

Sponsor

Huihua Xiong — full company profile →

Who can join

Adults 18 to 70, female only, with TNBC - Triple-Negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research.
Pont M, Marqués M, Sorolla A. · · 2024 · cited 18× · PMID 39769279 · DOI 10.3390/ijms252413518
Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.
Nedeljković M, Vuletić A, Mirjačić Martinović K. · · 2025 · cited 10× · PMID 40003864 · DOI 10.3390/ijms26041396
Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.
Deng X, Liu J. · · 2024 · cited 3× · PMID 39534580 · DOI 10.21037/tbcr-24-21

Verify or expand the search:

Other trials of Utidelone

Trials testing the same drug.

NCT07449481 — A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From · Phase 2 · not yet recruiting
NCT06764940 — A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With · Phase 2 · recruiting
NCT06683703 — Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases · Phase 2 · not yet recruiting
NCT06102824 — Organoid-based Functional Precision Therapy for Advanced Breast Cancer · Phase 2 · recruiting
NCT05983094 — Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer · Phase 2 · not yet recruiting

Other recruiting trials for TNBC - Triple-Negative Breast Cancer

Currently open trials in the same condition.

NCT07351487 — Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) · Phase 2 · recruiting
NCT06637306 — Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer · EARLY_PHASE1 · recruiting
NCT07046455 — Trop-2 Targeted PET Probes in Advanced TNBC · NA · recruiting
NCT06627712 — SBRT Combined With PD-1 Inhibitor and Chemotherapy in Early-stage TNBC · Phase 3 · recruiting
NCT06534762 — Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06125080 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huihua Xiong
Last refreshed: 9 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06125080.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing